Merck & Co. Inc. (MRK) News
Filter MRK News Items
MRK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MRK News Highlights
- MRK's 30 day story count now stands at 22.
- Over the past 16 days, the trend for MRK's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- LI, LUNG and VTRS are the most mentioned tickers in articles about MRK.
Latest MRK News From Around the Web
Below are the latest news stories about MERCK & CO INC that investors may wish to consider to help them evaluate MRK as an investment opportunity.
Amplifying the Power of Women in ChemistryMerck & Co., Inc. |
The Zacks Analyst Blog Highlights Merck, Intel, MercadoLibre, The Travelers Companies and HalliburtonMerck, Intel, MercadoLibre, The Travelers Companies and Halliburton are part of the Zacks top Analyst Blog. |
7 Healthcare Stocks to Buy for Long-Term Growth and StabilityThese healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio |
Merck (MRK) Stock Sinks As Market Gains: What You Should KnowIn the latest trading session, Merck (MRK) closed at $105.54, marking a -0.29% move from the previous day. |
Top Research Reports for Merck, Intel & MercadoLibreToday's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Intel Corporation (INTC) and MercadoLibre, Inc. (MELI). |
Merck, Viatris settle patent dispute over Januvia
|
7 Defensive Stocks to Buy During This Chaotic SpellWith turmoil erupting on Wall Street over the banking sector crisis, investors should turn to reliable defensive stocks to buy. |
Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023. |
Merck's (MRK) Co-formulation Therapy Fails Lung Cancer StudyData from a mid-stage study showed that Merck's (MRK) MK-7684A did not improve progression-free survival as a potential treatment for patients with metastatic non-small cell lung cancer. |
Merck's Keytruda Combo Therapy Less Effective Than Chemo In Lung Cancer Patients, Data Showshttps://cdn.benzinga.com/files/images/story/2023/03/17/mrk.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Merck & Co Inc's (NYSE: MRK) MK-7684A failed the open-label portion of a Phase 2 study KeyVibe-002 trial. MK-7684A, a combination of Keytruda (pembrolizumab) and in-house anti-TIGIT compound vibostolimab, did not improve patients' progression-free survival compared to chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) with progressive disease after treatment wit |